All Stories

AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday.

Mar 3, 2025 - 21:53
 0
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday.
Read More

Tags:

Previous Article

Emirates Bets on Cambodia as Chinese Travelers Stay Away

Next Article

STAT+: Top HHS spokesman abruptly resigns after reports of tensions with RFK Jr....

Related Posts

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid HHS handover: report

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid ...

Feb 20, 2025  0

Regulatory tracker: CDC investigates hospitalizations following use of Valneva's chikungunya vaccine

Regulatory tracker: CDC investigates hospitalizations f...

Feb 28, 2025  0

Sinusitis data from Amgen, AZ's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competition

Sinusitis data from Amgen, AZ's Tezspire spark 'best-in...

Mar 3, 2025  0